REG - ValiRx PLC - Inaphaea Evaluation and Commercial Use Agreement

ValiRxAnnouncement

03/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250203:nRSC6237Va&default-theme=true

RNS Number : 6237V  ValiRx PLC  03 February 2025

3 February 2025

ValiRx plc

 

("ValiRx" or the "Company")

 

Inaphaea Evaluation and Commercial Use Agreement

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial
Use agreement ("Agreement") with UK based Screenin3d Limited ("Screenin3D") to
provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial
use in Screenin3D's state-of-the-art UpScale(3D)lab-on-a-chip technology with
associated image analysis software.  The Agreement initially focusses on
establishment of three Triple Negative Breast Cancer in-vitro 3D tumour model
which will then be offered for commercial services by Screenin3D and Inaphaea.
Additional PDCs across Inaphaea's range of 66 cancer types can be added at any
time.

Inaphaea will be entitled to an upfront fee of £10,000 per PDC cell line upon
commercialisation of the models. Screenin3D have an option to buy the
commercial rights in relation to the PDCs and support future drug
development.  Both companies have also agreed to co-market their respective
services. The Agreement is for a period of 12 months initially and may be
extended in writing by mutual agreement.

Mark Eccleston, CEO of ValiRx commented "We are continuously looking for
commercial partners to accelerate Inaphaea's capabilities and market access.
Screenin3D's UpScale(3D)lab-on-a-chip platform and established customer base
is a perfect example of technology and commercial synergy for Inaphaea's
biobank of Patient Derived Cells. We look forward to the development of the
triple negative breast cancer models which will also be used to support
ValiRx's cytolytic peptide program through our partially owned subsidiary,
Cytolytix. The data sets generated, alongside standard of care drugs, will be
used to support commercialisation of the new UpScale(3D) PDC models and we
look forward to publishing the results with ScreenIn3D in due course."

Michele Zagnoni, CEO of Screenin3d Limited, commented "We are excited to
collaborate with Inaphaea to expand commercial opportunities for accelerating
drug discovery and translational research. Combining our patented UpScale(3D)
lab-on-a-chip technology with Inaphaea's biobank of Patient Derived Cells,
this partnership will offer novel and powerful preclinical services in
oncology and women's health, enabling us to facilitate large numbers of drug
tests on very small quantities of predictive human samples of disease."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investorhub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement                                      https://valirx.com/link/mPqJoy

 We encourage all investors to share questions on this announcement via our
 investor hub
 ValiRx plc                                                                   Tel: +44 115 784 0025

                                                                              www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                                                       Mark.Eccleston@valirx.com

 ScreenIn3D                                                                    https://screenin3d.com/ (https://screenin3d.com/)

 Dr Michele Zagnoni, CEO                                                      michele.zagnoni@screenin3d.com
 Cairn Financial Advisers LLP (Nominated Adviser)                             Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)                                     Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                                               +44 (0) 115 787 0206

                                                                              www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                                          lucy@vformation.biz

                                                                              sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUPUBPPUPAPGP